Prescient Therapeutics Ltd: Appendix 4G and Corporate Governance Statement
Prescient Therapeutics Ltd: June 2024 Quarterly Update and Appendix 4C
Prescient Therapeutics Ltd: Initial Director's Interest Notice
Prescient Therapeutics Ltd: Change of Director's Interest Notice
Prescient Therapeutics Ltd: PTX invited to present at international lymphoma forum
Prescient Therapeutics Ltd: March 2024 Quarterly Update and Appendix 4C
Prescient Therapeutics Ltd: PTX100 Ph1b results to be presented at specialist congress
Prescient Therapeutics Ltd: December 2023 Quarterly Update and Appendix 4C
Prescient Therapeutics Ltd: PTX-100 Ph1b results show excellent safety & efficacy in TCL
Prescient Therapeutics Ltd: Prescient Receives $2.4 Million R&D Tax Rebate
Prescient Therapeutics Ltd: PTX-100 abstract published online on ASH website
Prescient Therapeutics Ltd: September 2023 Quarterly Update and Appendix 4C
Prescient Therapeutics Ltd: PTX results to be presented at world's largest blood meeting
Prescient Therapeutics Ltd: Appendix 4G and Corporate Governance Statement
Prescient Therapeutics Ltd: June 2023 Quarterly Update and Appendix 4C
Prescient Therapeutics Ltd: Two PTX abstracts accepted at prestigious ISCT conference
Prescient Therapeutics Ltd: Initial Director's Interest Notice
Prescient Therapeutics Ltd: Change of Director's Interest Notices x3
Prescient Therapeutics Ltd: March 2023 Quarterly Update and Appendix 4C
Prescient Therapeutics Ltd: Change of Director's Interest Notices x2
No Data
No Data